Synolo Therapeutics
Synolo Therapeutics is seeking an experienced Principal Scientist to establish and advance analytical and biophysical characterization capabilities within the Protein Science team. The role involves collaborating with Biologics Discovery, Biology, CMC, and external CRO partners to generate molecular insights that guide protein engineering, candidate selection, and development strategy for next‑generation biologic therapeutics.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1-10 employees
Founded
2023
Synolo Therapeutics is advancing a new class of logic-gated, conditionally-active immunotherapies for cancer and autoimmune disease. Launched by RA Ventures (the venture-focused division of RA Capital Management) and leveraging a proprietary discovery platform, the company is rapidly building a pipeline of differentiated candidates that promise to be highly effective and safer than the current standard of care.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Synolo Therapeutics.
Synolo Therapeutics didn’t post a salary, so this is our estimate from similar listings.
74% above the average for this role
Associate Scientific Director / Principal Scientist — Molecular Interactions and Mass Spectrometry
Syngene International Limited
Principal Scientist
Almirall
Senior Scientist I
Generate:Biomedicines
Senior Scientist, Analytical Development, Biologics CMC
Exelixis
Biologics Formulation Research Internship
Varda Space Industries
Scientist/Senior Scientist, Protein Sciences & Biologics Development
Aragen Life Sciences